# ImmuneBro Therapeutics

Source: https://onco.cc/companies/immunebro-therapeutics/  
OnCo record `immunebro-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ImmuneBro Therapeutics in Chicago makes off-the-shelf immune cell treatments from healthy donors' T cells, combined with a T-cell engager, without gene editing. Its lead product, IBT1116, is being prepared for trials in B-cell cancers.

## Summary

ImmuneBro Therapeutics develops allogeneic T cell products from healthy donor T cells that integrate T cell therapy with a T cell engager, avoiding genome editing and CAR engineering, according to the company. Its one lead asset, IBT1116, is at the IND-enabling stage for relapsed or refractory B-cell malignancies and relapse after CD19 CAR-T therapy. In fiscal year 2026 NCI awarded it USD 1,351,438 under SBIR award 2R44CA281523-02 for its engager T cell approach to off-the-shelf T cell therapy.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Immunebro Therapeutics, Inc.; IMMUNEBRO THERAPEUTICS INC.
- HQ: Chicago, IL
- Type: cell-therapy
- Website: https://www.immunebro.com/

## Notes

- Read on immunebro.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://www.immunebro.com/
- NIH RePORTER: SBIR award 2R44CA281523-02: https://reporter.nih.gov/project-details/11314650

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [IBT1116](https://onco.cc/drugs/ibt1116/)

---
JSON: https://onco.cc/api/v1/entities/immunebro-therapeutics.json